Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
In patients with mRCC who received ICI-ICI, the occurrence of irAEs was associated with improved survival outcomes, whereas no such association was observed in patients who received ICI-TKI. This suggests that irAEs may reflect the favorable immune response specific to ICI-ICI therapy, whereas differences in the tumor microenvironment, particularly involving neutrophils, in ICI-TKI patients may influence treatment response.
Authors
- Shuya Kandori (ORCID: https://orcid.org/0000-0003-4621-8470)
- Hiromichi Sakurai
- Bunpei Isoda (ORCID: https://orcid.org/0009-0008-6483-3032)
- Hiromitsu Negoro (ORCID: https://orcid.org/0000-0003-1144-2755)
- Bryan J. Mathis (ORCID: https://orcid.org/0000-0002-9879-8289)
- Takamitsu Inoue (ORCID: https://orcid.org/0000-0002-1362-4344)
- Akira Joraku
- Tomoki Ishida
- Masanobu Shiga (ORCID: https://orcid.org/0000-0001-8610-0149)
- Hiroyuki Nishiyama (ORCID: https://orcid.org/0000-0001-7423-596X)
- Masahiro Iinuma (ORCID: https://orcid.org/0000-0003-1777-1525)
- Manabu Komine
- Masakazu Tsutsumi
- Shigeru Takahashi (ORCID: https://orcid.org/0009-0002-0028-1466)
- K Tanaka
- Akifumi Omiya
- Kotoe Matsuda
- Jun Miyazaki (ORCID: https://orcid.org/0000-0002-3618-0432)
Institutions
- University of Tsukuba (JP)
- National Hospital Organization Mito Medical Center (JP)
- Ibaraki Prefectural Central Hospital (JP)
- Tsukuba Medical Center Hospital (JP)
- Hitachi General Hospital (JP)
- International University of Health and Welfare (JP)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0337
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Astellas Pharma
- Chugai Pharmaceutical